View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 7, 2022

Guardant Health licenses genomic cancer assays to Adicon

The collaboration will provide biopharmaceutical firms with access to Guardant Health’s cancer tests portfolio.

Guardant Health has announced a strategic partnership with Chinese clinical laboratory firm Adicon to license its comprehensive genomic profiling (CGP) tests to accelerate the development of new cancer therapies in the country.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The collaboration will provide biopharmaceutical firms with access to Guardant Health’s cancer tests portfolio, which will help to advance their clinical trial and drug development programmes.

Under the deal, Guardant Health will grant a licence for Adicon to use its Guardant360 and GuardantOMNI tests, as well as Guardant360 TissueNext, a tissue-based biopsy for any solid cancerous tumour patients.

These tests will allow researchers to identify patients with cancers that have the appropriate molecular profile for their clinical programmes.

They will also facilitate patient screening, clinical trial enrolment and the providing of information regarding patient response, tumour evolution and resistance.

Additionally, biopharmaceutical firms will have access to Guardant Reveal, which is said to be the first blood-only test for detecting residual disease and monitoring cancer recurrence for early-stage cancer research and development.

Guardant Health co-CEO Helmy Eltoukhy said: “Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China.

“With Adicon’s extensive expertise in clinical laboratory services, we believe they are the ideal partner to help biopharmaceutical companies bring the next generation of cancer therapies to patients in the region.”

The company’s screening portfolio also includes the Shield test, which has been commercially launched and aims to address the needs of individuals that are eligible for cancer screening.

Last May, Guardant Health reported that its Guardant Reveal blood-only liquid biopsy test was able to identify patients with stage I-IV colorectal cancer (CRC) with increased risk of recurrence.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network